Elypta

The official account for Elypta. Our mission is to enable early detection and closer monitoring of cancer.

[Elypta @ElyptaDx]

Thank you so much for this recognition and support for what we do! This is such a boost for our team 👏🖖🏽

[The Roddenberry Foundation @RoddenberryFdn]

According to CEO Karl Bergman, these results made them “realize that there is an opportunity to detect more cancer cases earlier and in a more cost-efficient manner”

Welcome to the Roddenberry family!

Learn more about Elypta here: https://t.co/deevAgeFKv

(4 of 4)

[IKCC Kidney Cancer @IKCCorg]

Calling all patients with advanced #kidneycancer. Please consider taking part in this important piece of research by the European Oncology Nursing Society @cancernurseEU @nursGK704

[FirstWord HealthTech @fwhealthtech]

Elypta jumps deeper into multi-cancer Dx foray with series A https://t.co/DvZzlamseM #omics #oncology #healthtech #cancerdiagnostics #machinelearning .@ElyptaDx

[Elypta @ElyptaDx]

We just closed a $21 million series A! We couldn’t be more excited as it allows us to complete development in two indications - Multi Cancer Early Detection and surveillance of kidney cancer recurrence.

Delighted to have @BonnierVentures as our new lead

https://t.co/KohPEe91u1

[Elypta @ElyptaDx]

@SofinnovaVC @Siftedeu @iesogroup We appreciate the mention!

[Elypta @ElyptaDx]

Thank you @SofinnovaVC for highlighting us! 🙏👏

[Sofinnova Partners @SofinnovaVC]

Thanks @Siftedeu for the opportunity to contribute to this list of university spinouts that have caught our eye. Our picks include @iesogroup, Turbine and @elyptadx. (subscription required) https://t.co/gCQOU8f3f1 #biotech #healthtech #digitalmedicine

[Elypta @ElyptaDx]

Are you in Copenhagen? Do not miss our co-founder and CSO @gattofr at Talks at the Square at the @BioCPH on September 6!

Limited free tickets here: https://t.co/gMFxAZf8Rs

[Elypta @ElyptaDx]

@DrCraigGedye Valid question! Was any propensity score-matching done to balance patient characteristics between Cohort A and B? Is it known what was the most common decision criterion to allocate a mRCC patient to active surveillance?

[Elypta @ElyptaDx]

Session starts soon! #EAU21
https://t.co/xzaAJrUtwc

[Elypta @ElyptaDx]

Our CSO @gattofr is presenting at the #EAU21 Poster Session 22 at 5.46 PM CET the study "Urine free glycosaminoglycans as monitoring biomarkers in confined renal cell carcinoma - A prospective observational study" https://t.co/cugSPTB09i

[Elypta @ElyptaDx]

Our CSO @gattofr is presenting at the #EAU21 Poster Session 22 at 5.46 PM CET the study "Urine free glycosaminoglycans as monitoring biomarkers in confined renal cell carcinoma - A prospective observational study" https://t.co/cugSPTB09i

[Elypta @ElyptaDx]

Credit to the PIs: @DrDabestani, Axel Bex, @arihakimi , @minerviniandre , Tommy Nielsen, @virajmaster , @Ric_Campi , Lars Lund, @nairajesh , Jose Karam, @u_capitanio , @grantissimus , @SatishMaddineni , Neil Barber, @markr1004 , @NessnAzawi , @Lorenzo_marconi, @Peura65

[Elypta @ElyptaDx]

100 patients! Elypta is proud to announce that our flagship study AURORAX-0087A (EU grant 849251) has today included its 100th patient.

So grateful to the principal investigators, their staff, and patients for their incredible efforts! https://t.co/RGLgajLG3X

[Elypta @ElyptaDx]

We shared some exciting results at ASCO earlier in June. A study across 14 cancers and more than 1500 samples in total showed our GAGome platform’s ability to detect 1/3 stage 1 tumors. A breakthrough in our mission to enable early detection of cancer. https://t.co/fAt9mdy3fz

[Elypta @ElyptaDx]

Indeed, we really look forward to sharing our latest results!

[nina.capital @ninacapital]

Mark your calendar! 4-8 June @ElyptaDx announced that two abstracts using its novel metabolism-based #liquidbiopsy will be presented at the 2021 virtual @ASCO conference. https://t.co/cgPrFiUeHT #wearenina

[nina.capital @ninacapital]

🥁 Calling #healthtech entrepreneurs, investors, advisors or professionals in a corporate environment in Europe and/or in the US! We would appreciate if you could fill out this survey to support our analyst intern @lesley_farrah for her Master thesis. https://t.co/fm8ktTskFs

[Elypta @ElyptaDx]

There is a very nice Medtech Insight feature on us out today. Thanks for the spotlight! #kidneycancer #liquidbiopsy #metabolism

[Medtech Insight, Citeline Commercial @Medtech_Insight]

Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
https://t.co/VZglnzqQsn

[Elypta @ElyptaDx]

We have some good news to share.

Our glycosaminoglycan profiling kit is now available as a service for the research community. GAGs play a role in many conditions and we believe standardized, accurate quantification can help others explore this.

https://t.co/A8hqaaTVXt

[Elypta @ElyptaDx]

Very nice piece on the story behind our founding. Thanks for the opportunity to share it!

[nina.capital @ninacapital]

It's OUT! Part 4 of our #spinoff series is here! Learn more about @ElyptaDx, a solution measuring metabolic #biomarkers in blood and urine using machine learning to detect #cancer, founded by scientists from #Chalmers university. https://t.co/6peZ9kP2VV #wearenina

[Elypta @ElyptaDx]

Thanks! Very proud team here this week 🙏

[nina.capital @ninacapital]

Congrats @ElyptaDx team for being included in Sweden's top 33 tech #startups by @nyteknik! #wearenina #oncology #nephrology
https://t.co/rdA6ikHRPq

[Elypta @ElyptaDx]

Elypta is happy to share the progress on the AURORAX-0087A study (co-funded by EU SME Instr. 2 Grant No 849251) that is now active in nearly all 16 sites! #liquidbiopsy #rcc #eu #horizon2020